| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 239.92M | 239.92M | 133.83M | 111.44M | 77.77M | 90.53M |
| Gross Profit | 24.63M | 24.63M | 7.74M | 8.61M | 3.76M | -5.18M |
| EBITDA | 15.33M | 15.33M | 382.00K | 3.58M | -283.00K | -3.93M |
| Net Income | 12.77M | 12.77M | 1.57M | 2.33M | -391.00K | -6.21M |
Balance Sheet | ||||||
| Total Assets | 175.10M | 175.10M | 98.92M | 85.29M | 71.84M | 86.15M |
| Cash, Cash Equivalents and Short-Term Investments | 94.35M | 94.35M | 42.03M | 23.37M | 14.09M | 32.54M |
| Total Debt | 2.85M | 2.85M | 4.45M | 3.36M | 4.85M | 7.12M |
| Total Liabilities | 123.13M | 123.13M | 59.90M | 47.87M | 36.83M | 50.73M |
| Stockholders Equity | 51.97M | 51.97M | 39.01M | 37.42M | 35.02M | 35.43M |
Cash Flow | ||||||
| Free Cash Flow | 55.97M | 55.97M | 17.64M | 8.83M | -15.26M | -13.48M |
| Operating Cash Flow | 57.23M | 57.23M | 19.62M | 9.41M | -14.68M | -10.35M |
| Investing Cash Flow | 1.37M | 1.37M | 176.00K | 1.25M | -1.53M | -2.74M |
| Financing Cash Flow | -6.08M | -6.08M | -1.52M | -1.62M | -2.29M | -1.97M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$256.00M | 3.41 | 27.58% | ― | 81.81% | 724.56% | |
64 Neutral | HK$158.73M | 6.99 | 8.56% | 23.73% | -32.31% | -51.89% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
60 Neutral | HK$157.72M | 5.38 | 2.70% | ― | -27.58% | -18.28% | |
49 Neutral | HK$130.14M | -10.99 | -0.68% | 7.69% | -33.92% | -94.74% | |
40 Underperform | HK$158.88M | -1.95 | -46.27% | ― | -63.83% | 36.12% |
Kwan Yong Holdings Limited has secured a construction contract worth approximately SGD96 million from Singapore’s Ministry of Health to develop a new nursing home at Alexandra Health Campus, with work scheduled to begin in March 2026. The award, obtained in the ordinary course of business, underscores the Group’s continued role in public-sector healthcare infrastructure, though the company does not expect the project to have a material impact on its net tangible assets or earnings per share for the financial year ending 30 June 2026, and the final revenue may differ from the stated contract sum due to contingent and provisional amounts.
The most recent analyst rating on (HK:9998) stock is a Hold with a HK$0.40 price target. To see the full list of analyst forecasts on Kwan Yong Holdings Limited stock, see the HK:9998 Stock Forecast page.
Kwan Yong Holdings Limited has announced an updated composition of its board of directors, comprising four executive directors, one non-executive director and three independent non-executive directors, effective 7 January 2026. The company has also confirmed the membership and chairmanship of its key governance bodies – the Audit, Remuneration and Nomination Committees – signalling a formalised governance structure and delineation of oversight responsibilities across its directors, which may strengthen board independence, risk management and remuneration oversight for shareholders and other stakeholders.
The most recent analyst rating on (HK:9998) stock is a Hold with a HK$0.40 price target. To see the full list of analyst forecasts on Kwan Yong Holdings Limited stock, see the HK:9998 Stock Forecast page.
Kwan Yong Holdings Limited has reshaped its board’s nomination committee, appointing independent non-executive director Fong Heng Boo as a new member and removing non-executive director Chou Sean Yu from the committee with effect from 7 January 2026. The reconfigured nomination committee now consists of three independent non-executive directors and two executive directors, maintaining a majority of independent members in line with Hong Kong listing requirements, a move the board believes will strengthen board effectiveness, enhance diversity, and bolster the company’s overall corporate governance framework.
The most recent analyst rating on (HK:9998) stock is a Hold with a HK$0.40 price target. To see the full list of analyst forecasts on Kwan Yong Holdings Limited stock, see the HK:9998 Stock Forecast page.
Kwan Yong Holdings Limited has announced a board-level reshuffle, redesignating independent non-executive director (INED) Chou Sean Yu as a non-executive director (NED) with effect from 19 December 2025. Chou, a veteran commercial litigator and managing partner of WongPartnership LLP with more than three decades of experience, will step down as chairman of the remuneration committee but remain a member of that committee, as well as continuing to serve on the audit and nomination committees. Under a new three-year appointment, he will receive an annual director’s fee of SGD35,000, reflecting his revised role and responsibilities. Concurrently, independent non-executive director Lim Ah Lay has been appointed chairman of the remuneration committee, signalling a rebalancing of independent oversight within the board’s key governance structures while maintaining continuity in committee membership and preserving the company’s existing governance framework.
The most recent analyst rating on (HK:9998) stock is a Hold with a HK$0.40 price target. To see the full list of analyst forecasts on Kwan Yong Holdings Limited stock, see the HK:9998 Stock Forecast page.
Kwan Yong Holdings Limited has announced the current composition of its board of directors, effective 19 December 2025, led by Chairman and Chief Executive Officer Mr. Kwan Mei Kam alongside three other executive directors, one non-executive director and three independent non-executive directors. The company has also detailed the membership of its Audit, Remuneration and Nomination Committees, assigning chairmanships and memberships among independent and non-executive directors, a move that underlines its emphasis on corporate governance, oversight and board independence for its shareholders and other stakeholders.
The most recent analyst rating on (HK:9998) stock is a Hold with a HK$0.40 price target. To see the full list of analyst forecasts on Kwan Yong Holdings Limited stock, see the HK:9998 Stock Forecast page.
Kwan Yong Holdings Limited has reported that all resolutions tabled at its 18 December 2025 annual general meeting in Singapore were approved by shareholders by overwhelming majorities. Investors backed the adoption of the audited financial statements for the year ended 30 June 2025, granted the board wide-ranging mandates to issue and repurchase shares, approved a final dividend of HK$0.02 per share, re-elected two executive directors and one independent non-executive director, authorised the board to set directors’ pay and re-appointed Ernst & Young LLP as auditor. Shareholders also passed a special resolution to adopt a third amended and restated memorandum and articles of association, giving the board a refreshed constitutional framework and broad authority to implement the changes, underscoring strong shareholder support for the company’s governance and capital management flexibility.
The most recent analyst rating on (HK:9998) stock is a Hold with a HK$0.40 price target. To see the full list of analyst forecasts on Kwan Yong Holdings Limited stock, see the HK:9998 Stock Forecast page.
Kwan Yong Holdings Limited announced that its subsidiary, Kwan Yong Construction Pte Ltd, has secured a construction contract worth approximately SGD56.5 million from the Ministry of Health of Singapore for the development of a nursing home at Bukit Purmei Avenue. The project is set to begin in December 2025. This contract is part of the company’s regular business activities and is not anticipated to significantly impact its financial metrics for the fiscal year ending June 2026, though the actual revenue may vary from the contract sum.
The most recent analyst rating on (HK:9998) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on Kwan Yong Holdings Limited stock, see the HK:9998 Stock Forecast page.
Kwan Yong Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for December 18, 2025, in Singapore. The meeting will address several resolutions, including the adoption of audited financial statements and the authorization for directors to allot, issue, and deal with additional shares. Additionally, the company seeks approval to repurchase its shares, with limits set at 20% for share issuance and 10% for share repurchase. These resolutions aim to provide the company with flexibility in managing its capital structure, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (HK:9998) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on Kwan Yong Holdings Limited stock, see the HK:9998 Stock Forecast page.